文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

CBCT引导在线自适应SBRT治疗前列腺癌的剂量学影响

Dosimetric impact of CBCT-guided online adaptive stereotactic body radiotherapy for prostate cancer: a 250-fraction retrospective analysis.
PubMed 文献 · Radiother Oncol · 2026-11-01

该研究回顾性分析50例在Varian Ethos平台接受前列腺SBRT的患者,逐分次比较计划方案与自适应方案的剂量学差异。结果显示自适应计划靶区覆盖更高,但计划方案在83%分次中仍处于处方剂量约3%以内;在线自适应主要提升对偶发但临床显著剂量偏差的稳健性,而非在所有分次中持续优于非自适应计划。

要点

  • 自适应计划靶区覆盖优于计划方案,但多数分次差异有限
  • 计划方案在3.6%分次出现PTV D95%下降20%,11%分次覆盖下降>5%
  • 严格按计划目标执行时自适应分次达标数明显多于计划分次

核心结论

  • CBCT引导在线自适应前列腺SBRT主要改善对偶发但临床显著剂量偏差的稳健性,而非在多数分次中提供一致优势。

研究设计与样本

  • 单中心回顾性分析,50例前列腺癌患者,Varian Ethos平台,逐分次配对比较计划方案与自适应方案,采用Wilcoxon符号秩检验。

主要发现

  • 自适应计划靶区覆盖高于计划方案(p < 0.001),计划方案在83%分次中仍处于处方剂量约3%以内。
  • 计划方案在3.6%分次出现PTV D95%下降20%,11%分次覆盖下降>5%,自适应分次无类似大幅偏差。
  • 仅1例患者累积D95%下降约5%;OAR差异总体较小,ART主要减少偶发约束违反。

关键数值与推荐

  • 严格按计划目标执行时,234个自适应分次达标,计划分次为62个,离线再归一化后提升至135个。
  • 对PTV D95%≤80%的分次进行累积剂量重建。

临床怎么用

  • 可用于识别计划方案可能出现显著靶区覆盖不足的分次,以支持自适应决策而非对所有分次常规采用ART。

局限性

  • 为单中心回顾性分析,样本为50例前列腺癌患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To quantitatively evaluate the dosimetric benefit of CBCT-guided online adaptive radiotherapy (ART) for prostate SBRT compared with non-adaptive treatment planning, with emphasis on target coverage preservation and organ-at-risk (OAR) sparing. METHODS AND MATERIALS: Fifty prostate patients treated on the Varian Ethos platform were retrospectively analyzed. For each fraction, scheduled plans (reference plan recalculated on daily anatomy) were compared with adapted plans (daily reoptimized plans). Target coverage was assessed using PTV D95% while bladder and rectal metrics were evaluated using institutional constraints. Fraction-level paired comparisons used the Wilcoxon signed-rank test. Fractions with substantial scheduled-plan under-coverage (PTV D95% ≤80%) underwent cumulative dose reconstruction. RESULTS: Adaptive plans achieved higher target coverage than scheduled plans (p < 0.001), although scheduled plans remained within ∼3% of prescription in 83% of fractions. Scheduled plans demonstrated a 20% reduction in PTV D95% in 3.6% of fractions and >5% coverage reduction in 11%, whereas no adaptive fractions showed similarly large deviations. Cumulative scheduled-only dose remained near prescription for most affected patients, with only one patient demonstrating a cumulative D95% reduction of ∼5%. OAR differences were small overall, with ART planning mainly reducing occasional constraint violations. Strict application of planning objectives resulted in 234 adaptive fractions meeting goals versus 62 scheduled fractions, improving to 135 with offline renormalization. CONCLUSIONS: CBCT-guided ART for prostate SBRT primarily improves robustness against infrequent but clinically significant dosimetric deviations rather than providing consistent superiority across most fractions.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Eldib A, Clark AT, Panetta J, et al. Dosimetric impact of CBCT-guided online adaptive stereotactic body radiotherapy for prostate cancer: a 250-fraction retrospective analysis. Radiother Oncol. 2026. PMID: 42967541. doi:10.1016/j.radonc.2026.111857

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。